MX386481B - Imidazopirrolopiridina como inhibidores de la familia de quinasas jak - Google Patents

Imidazopirrolopiridina como inhibidores de la familia de quinasas jak

Info

Publication number
MX386481B
MX386481B MX2019007084A MX2019007084A MX386481B MX 386481 B MX386481 B MX 386481B MX 2019007084 A MX2019007084 A MX 2019007084A MX 2019007084 A MX2019007084 A MX 2019007084A MX 386481 B MX386481 B MX 386481B
Authority
MX
Mexico
Prior art keywords
imidazopyrrolopyridine
kinases
inhibitors
jak family
methods
Prior art date
Application number
MX2019007084A
Other languages
English (en)
Other versions
MX2019007084A (es
Inventor
Aihua Wang
Genesis M Bacani
Jennifer D Venable
Kevin D Kreutter
Kristi Leonard
Mark S Tichenor
Mark Seierstad
Michele C Rizzolio
Paul J Krawczuk
Russel C Smith
Tatiana Koudriakova
Wenying Chai
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019007084A publication Critical patent/MX2019007084A/es
Publication of MX386481B publication Critical patent/MX386481B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de 2-((1r,4r)-4-(imidazo[4,5-d]pirrolo[2,3-b]piridin-1(6H)- il)ciclohexil)acetonitrilo, composiciones farmaceuticas que los contienen, metodos para elaborarlos, y metodos para usarlos que incluyen metodos para tratar enfermedades, desordenes y condiciones mediadas por JAK, tales como la enfermedad inflamatoria del intestino.
MX2019007084A 2016-12-16 2017-12-15 Imidazopirrolopiridina como inhibidores de la familia de quinasas jak MX386481B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662435639P 2016-12-16 2016-12-16
US201762592747P 2017-11-30 2017-11-30
US201762596636P 2017-12-08 2017-12-08
PCT/US2017/066754 WO2018112382A1 (en) 2016-12-16 2017-12-15 Imidazopyrrolopyridine as inhibitors of the jak family of kinases

Publications (2)

Publication Number Publication Date
MX2019007084A MX2019007084A (es) 2019-10-15
MX386481B true MX386481B (es) 2025-03-18

Family

ID=60937954

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007084A MX386481B (es) 2016-12-16 2017-12-15 Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
MX2021011438A MX2021011438A (es) 2016-12-16 2019-06-14 Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011438A MX2021011438A (es) 2016-12-16 2019-06-14 Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.

Country Status (19)

Country Link
US (2) US10981911B2 (es)
EP (1) EP3555096B1 (es)
JP (2) JP7153647B2 (es)
KR (1) KR102565224B1 (es)
CN (2) CN110312719B (es)
AU (2) AU2017377072B2 (es)
CL (1) CL2019001633A1 (es)
CO (1) CO2019006858A2 (es)
EC (1) ECSP19047936A (es)
ES (1) ES2935392T3 (es)
IL (2) IL295461A (es)
JO (1) JOP20190144A1 (es)
MX (2) MX386481B (es)
MY (1) MY196805A (es)
NI (1) NI201900061A (es)
PE (1) PE20191499A1 (es)
PH (1) PH12019501355A1 (es)
UA (1) UA123689C2 (es)
WO (1) WO2018112382A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3640251T (lt) 2016-10-24 2022-03-10 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
AU2017377069B2 (en) * 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
AU2018208516B2 (en) 2017-01-11 2021-07-08 Aqilion Ab Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
US11180575B2 (en) 2018-12-28 2021-11-23 Corn Products Development, Inc. Thermally inhibited starch and process for making
IL279348B2 (en) 2018-06-15 2026-01-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
EP3996183A4 (en) 2019-07-30 2023-01-04 LG Chem, Ltd. COMPOSITE SEPARATOR FOR ELECTROCHEMICAL DEVICE AND ELECTROCHEMICAL DEVICE THEREOF
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
GB201914779D0 (en) * 2019-10-11 2019-11-27 Oxford Medical Products Ltd Polymer compositions
JP7719796B2 (ja) 2020-04-24 2025-08-06 アストラゼネカ・アクチエボラーグ 医薬製剤
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
KR20230057341A (ko) * 2020-07-02 2023-04-28 인사이트 코포레이션 Jak2 v617f 억제제로서 삼환계 우레아 화합물
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
PE20251706A1 (es) 2022-03-17 2025-07-02 Incyte Corp Compuestos de urea triciclica como inhibidores de v617f de jak2
WO2023194841A1 (en) * 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in ulcerative colitis
WO2023194842A1 (en) * 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis
WO2023194840A1 (en) * 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in covid-19
WO2023248010A2 (en) 2022-06-23 2023-12-28 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
CN117924326B (zh) * 2024-01-23 2025-01-21 英矽智能科技(上海)有限公司 一类抑制jak和phd的三并环类化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
CN1167702C (zh) 1999-04-23 2004-09-22 史密丝克莱恩比彻姆有限公司 5-[4-[2-n-甲基-n-(2-吡啶基)氨基]乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的多晶型物
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AR040233A1 (es) 2002-05-31 2005-03-23 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
ES2449197T5 (es) 2005-07-01 2022-04-28 Wyeth Llc Formas cristalinas de 4-[(2,4-dicloro-5-metoxifenil)amino]-6-metoxi-7-[3-(4-metil-1-piperazinil)propoxi]-3- quinolincarbonitrilo y procedimientos de preparación de las mismas
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
AU2012201894A1 (en) * 2005-12-13 2012-04-19 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2271646A1 (en) * 2008-03-31 2011-01-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
HUE028347T2 (en) 2008-06-10 2016-12-28 Abbvie Inc Tricyclic compounds
JP5567137B2 (ja) 2009-09-03 2014-08-06 ブリストル−マイヤーズ スクイブ カンパニー Ｊａｋ２阻害剤、ならびに骨髄増殖性疾患および癌の治療のためのそれらの使用
KR20120102724A (ko) * 2009-12-01 2012-09-18 아보트 러보러터리즈 신규한 트리사이클릭 화합물
ME02800B (me) * 2009-12-01 2018-01-20 Abbvie Inc Nova triciklična jedinjenja
US8461328B2 (en) 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
US8841078B2 (en) 2010-02-10 2014-09-23 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
JP6248948B2 (ja) 2013-02-08 2017-12-20 日産化学工業株式会社 ３環性ピロロピリジン化合物及びｊａｋ阻害剤
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
AU2015260349B2 (en) 2014-05-14 2019-02-21 Nissan Chemical Industries, Ltd. Tricyclic compound and JAK inhibitor
JP6692836B2 (ja) 2015-05-28 2020-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのナフチリジン化合物
US20180321235A1 (en) 2015-11-04 2018-11-08 Mayo Foundation For Medical Education And Research Methods and materials for treating autoimmune conditions
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
LT3640251T (lt) 2016-10-24 2022-03-10 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
EP3555105B1 (en) 2016-12-16 2020-10-28 Eli Lilly and Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
WO2018109074A1 (en) 2016-12-16 2018-06-21 Nestec Sa Oligosaccharides for flavour generation
AU2017377069B2 (en) 2016-12-16 2020-07-23 Janssen Pharmaceutica Nv Small molecule inhibitors of the JAK family of kinases
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
BR112019011211A2 (pt) 2016-12-16 2019-10-15 Basf Se compostos de fórmula i, composição, métodos para combater ou controlar pragas invertebradas, para proteger plantas em crescimento de ataque ou infestação por pragas invertebradas, semente, uso de um composto e método para tratar ou proteger um animal
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
AU2018208516B2 (en) 2017-01-11 2021-07-08 Aqilion Ab Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
TWI778050B (zh) 2017-04-21 2022-09-21 美商醫肯納腫瘤學公司 吲哚ahr抑制劑及其用途
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US20200338051A1 (en) * 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor
AU2022233254A1 (en) * 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders

Also Published As

Publication number Publication date
WO2018112382A1 (en) 2018-06-21
IL295461A (en) 2022-10-01
JP7153647B2 (ja) 2022-10-14
JP2022106844A (ja) 2022-07-20
MY196805A (en) 2023-05-03
NI201900061A (es) 2019-10-21
AU2017377072A1 (en) 2019-06-27
ES2935392T3 (es) 2023-03-06
US10981911B2 (en) 2021-04-20
CN110312719B (zh) 2022-04-15
US20210206768A1 (en) 2021-07-08
BR112019012264A2 (pt) 2020-01-28
ECSP19047936A (es) 2019-07-31
AU2021273566A1 (en) 2021-12-16
EP3555096A1 (en) 2019-10-23
JP7441264B2 (ja) 2024-02-29
CL2019001633A1 (es) 2019-10-04
PE20191499A1 (es) 2019-10-22
EP3555096B1 (en) 2022-11-23
CN110312719A (zh) 2019-10-08
US11827638B2 (en) 2023-11-28
CO2019006858A2 (es) 2019-07-10
JP2020502141A (ja) 2020-01-23
MX2019007084A (es) 2019-10-15
CN114685505A (zh) 2022-07-01
KR102565224B1 (ko) 2023-08-08
CA3047311A1 (en) 2018-06-21
UA123689C2 (uk) 2021-05-12
IL267215A (en) 2019-08-29
KR20190092560A (ko) 2019-08-07
MX2021011438A (es) 2021-10-13
US20190322665A1 (en) 2019-10-24
PH12019501355A1 (en) 2020-03-02
AU2017377072B2 (en) 2021-08-26
AU2021273566B2 (en) 2023-04-13
IL267215B (en) 2022-09-01
JOP20190144A1 (ar) 2019-06-16

Similar Documents

Publication Publication Date Title
MX386481B (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak
PH12019501254A1 (en) Small molecule inhibitors of the jak family of kinases
EA202090659A1 (ru) СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ
PH12020551984A1 (en) Small molecule inhibitors of the jak family of kinases
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
EA201791369A1 (ru) Твердые формы конденсированных гетероароматических пирролидинонов
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
EA201991472A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
EA201991473A1 (ru) Имидазопирролопиридин в качестве ингибиторов киназ семейства jak
TH1901003656A (th) สารยับยั้งที่มีโมเลกุลขนาดเล็กของวงศ์ jak ของไคเนส
CR20190283A (es) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
EA202190047A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
AR114969A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА
MA50430B1 (fr) Composés d'imidazo[4,5-d]pyrrolo[2,3-b]pyridine comme inhibiteurs de janus kinases